A putative class action has been lodged in New Jersey against the Princeton-based maker of the cholesterol-reducing drug Atorvastatin, which was found to be tainted with glass particles.
December 05, 2012 at 12:00 AM
1 minute read
A putative class action has been lodged in New Jersey against the Princeton-based maker of the cholesterol-reducing drug Atorvastatin, which was found to be tainted with glass particles.
The suit was filed on Nov. 29, the day after Ranbaxy Pharmaceuticals announced that it had recalled several lots of the drug and the day before the Food & Drug Administration issued a public advisory.
Presented by BigVoodoo
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
